Multiple System Atrophy Market Analysis

The market is segmented by diagnosis into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test, and others, out of which, the magnetic resonance imaging (MRI) segment is anticipated to hold the largest share in the global multiple system atrophy (MSA) market on account of the high usage of MRI techniques for differentiation of systemic atrophy with Parkinson’s disease, and its usefulness in tracking the progression of multiple system atrophy. Along with this, the segment for tilt table test is also predicted to occupy a significant market share during the forecast period owing to the rising use of this test to document the extent of blood pressure irregularities, which is fundamental for diagnosing systemic atrophies.

Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:

By Type	Parkinsonian Cerebellar
By Diagnosis	Magnetic Resonance Imaging (MRI) Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Tilt Table Test Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of multiple system atrophy is estimated at USD 151.24 million.

Multiple System Atrophy (MSA) Market size was valued at USD 145.67 million in 2024 and is likely to cross USD 258.16 million by 2037, registering more than 4.5% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is expected to dominate majority revenue share by 2037, on the back of increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region.

The major players in the market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, and others.

Multiple System Atrophy Market Analysis